KP Tissue Inc. (KPT) (TSX: KPT) reports the Q1 2022 financial and
operational results of KPT and Kruger Products L.P. (KPLP). Kruger
Products is Canada's leading manufacturer of quality tissue
products for the Consumer market (Cashmere®, Purex®, SpongeTowels®,
Scotties®, White Swan® and BonterraTM) and the Away-From-Home (AFH)
market and continues to expand in the U.S. Consumer market with the
White Cloud® brand and premium private label products. KPT
currently holds a 14.3% interest in KPLP.
KPLP Q1 2022 Business and Financial
Highlights
- Revenue was $398.7 million in Q1
2022 compared to $310.4 million in Q1 2021, an increase of $88.3
million or 28.5%.
- Adjusted EBITDA1 was $29.1 million
in Q1 2022, compared to $37.5 million in Q1 2021, a decrease of
22.4%.
- Net income was $1.4 million in Q1
2022 compared to $6.8 million in Q1 2021, a decrease of $5.4
million.
- Declared a quarterly dividend of
$0.18 per share to be paid on July 15, 2022.
“We delivered strong sales growth of 28.5%
year-over-year in the first quarter of 2022, driven by an ongoing
market recovery, increased capacity driven by Sherbrooke and a
pricing increase mainly impacting our Canadian operations. Robust
top-line growth was tempered by escalating inflation across many
essential cost items such as pulp, freight, natural gas, packaging
and labour,” stated KP Tissue’s Chief Executive Officer, Dino
Bianco.
“To counter inflationary pressure, we have
adopted a multi-faceted strategy based on further price increases
across all segments, cash management through reductions in working
capital and discretionary capital spending, as well as incremental
productivity programs. We believe price increases, combined with
the aforementioned cost-saving initiatives, should begin catching
up with inflation in the second half of the year.”
“In light of price increases in the marketplace,
we believe it’s vital to continue supporting our brands through
targeted innovation and marketing. Accordingly, we are seeing
strong distribution for our new sustainably focused brand,
Bonterra. Recently upgraded Purex® and Cashmere UltraLuxe® TAD
products are also tracking well against expectations, while
SpongeTowels UltraPro® continues to drive share with consumers
since its introduction last year. More recently, we expanded the
distribution of re-launched White Cloud in the United States as we
continue to build that brand,” Mr. Bianco concluded.
Outlook for Q2 2022We
anticipate continued momentum in Q2 sales in both Consumer and AFH.
However, cost inflation and supply chain issues are expected to
continue to impact the business and as a result Q2 2022 Adjusted
EBITDA1 is expected to be well below Q1 2022 until selling price
increases can restore margins in the second half of the year.
KPLP Q1 2022 Financial
ResultsRevenue was $398.7 million in Q1 2022 compared to
$310.4 million in Q1 2021, an increase of $88.3 million or 28.5%.
The increase in revenue was due to selling price increases in all
segments and regions and higher sales volume in the Consumer
segment compared to the year ago quarter that saw lower sales as a
result of the de-stocking of tissue inventories by both retailers
and consumers. The AFH segment also had significantly higher sales
volume compared to Q1 2021 as the business continues to recover
from the impact of COVID-19.
Cost of sales was $363.8 million in Q1 2022
compared to $263.3 million in Q1 2021, an increase of $100.5
million or 38.2%. Manufacturing costs increased primarily due to
higher sales volumes, increased pulp costs, the impact of labour
shortages in Memphis manufacturing, the unfavourable impact of
overhead absorption as inventory levels were lower than the year
ago quarter, along with higher depreciation expense and
inflation.
1 Adjusted EBITDA is a non-GAAP financial
measure. Refer to the Non-GAAP Financial Measures section of this
news release for more information on these measures
These increases were partially offset by more
in-house production in AFH. Freight costs increased significantly
compared to Q1 2021 primarily due to increased freight rates
resulting from cost inflation and supply issues across North
America and also higher sales volumes. As a percentage of revenue,
cost of sales was 91.3% in Q1 2022 compared to 84.8% in Q1
2021.
Selling, general and administrative (SG&A)
expenses were $28.9 million in Q1 2022 compared to $27.8 million in
Q1 2021, an increase of $1.1 million or 3.9%. The increase was
primarily due to higher advertising and promotion expenses. As a
percentage of revenue, SG&A expenses were 7.2% in Q1 2022
compared to 8.9% in Q1 2021.
Adjusted EBITDA1 was $29.1 million in Q1 2022
compared to $37.5 million in Q1 2021, a decrease of $8.4 million or
22.4%. The decrease was primarily due to higher pulp prices and
other inflation, overhead absorption, labour shortages in Memphis
manufacturing and higher freight rates, partially offset by higher
sales volume and selling price increases.
Net income was $1.4 million in Q1 2022 compared
to $6.8 million in Q1 2021, a decrease of $5.4 million. The
decrease was primarily due to lower Adjusted EBITDA1 of $8.4
million as discussed above, higher interest expense and other
finance costs and higher depreciation and amortization, partially
offset by higher income tax recovery and higher other income.
KPLP Q1 2022 LiquidityTotal
liquidity, representing cash and availability under the revolving
credit agreements, was $206.9 million as of March 31, 2022. In
addition, $76.4 million of cash was held by KPLP for the TAD
Sherbrooke and Sherbrooke Expansion Projects.
KPT Q1 2022 Financial
ResultsKPT had a net income of $1.0 million in Q1 2022.
Included in the net income was $0.2 million representing KPT’s
share of KPLP’s net income, and a dilution gain of $0.1 million,
depreciation expense of $1.3 million related to adjustments to
carrying amounts on acquisition and an income tax recovery of $2.0
million.
Dividends on Common
Shares The
Board of Directors of KPT declared a quarterly dividend of $0.18
per share to be paid on July 15, 2022 to shareholders of record at
the close of business on June 30, 2022.
Additional InformationFor
additional information please refer to Management’s Discussion and
Analysis (MD&A) of KPT and KPLP for the first quarter ended
March 31, 2022 available on SEDAR at www.sedar.com or our website
at www.kptissueinc.com.
First Quarter Results Conference Call
InformationKPT will hold its first quarter conference call
on Thursday, May 12, 2022 at 8:30 a.m. Eastern Time.
Via telephone: 1-800-599-5188 or
647-365-5897
Via the internet at: www.kptissueinc.com
Presentation material referenced during the
conference call will be available at www.kptissueinc.com.
A rebroadcast of the conference call will be
available until midnight, May 19, 2022 by dialing 1-800-770-2030 or
647-362-9199 and entering passcode 9884406.
The replay of the webcast will remain available
on the website until midnight, May 19, 2022.
About KP Tissue Inc. (KPT)KPT
was created to acquire, and its business is limited to holding, a
limited partnership interest in KPLP, which is accounted for as an
investment on the equity basis. KPT currently holds a 14.3%
interest in KPLP. For more information visit
www.kptissueinc.com.
About Kruger Products L.P.
(KPLP)KPLP is Canada's leading manufacturer of quality
tissue products for household, industrial and commercial use. KPLP
serves the Canadian consumer market with such well-known brands as
Cashmere®, Purex®, SpongeTowels®, Scotties®, White Swan® and
Bonterra™. In the U.S., KPLP manufactures the White Cloud® brand,
as well as many private label products. The Away-From-Home division
manufactures and distributes high-quality, cost-effective product
solutions to a wide range of commercial and public entities. KPLP
has approximately 2,700 employees and operates nine FSC®
COC-certified (FSC® C-104904) production facilities in North
America. For more information visit www.krugerproducts.ca.
Non-GAAP Financial MeasuresThis
press release uses certain non-GAAP financial measures which KPLP
believes provide useful information to management of KPLP and the
readers of the financial information in measuring the financial
performance and financial condition of KPLP. These measures do not
have a standardized meaning prescribed by GAAP and therefore may
not be comparable to similarly titled measures presented by other
companies. An example of such a measure is Adjusted EBITDA.
Adjusted EBITDA is not a measurement of operating performance
computed in accordance with GAAP and should not be considered as a
substitute for operating income, net income or cash flows from
operating activities computed in accordance with GAAP. “Adjusted
EBITDA” is calculated by KPLP as net income (loss) before (i)
interest expense and other finance costs, (ii) income taxes, (iii)
depreciation, (iv) amortization, (v) impairment (gain on sale) of
non-financial assets, (vi) loss (gain) on disposal of property,
plant and equipment, (vii) foreign exchange loss (gain), (viii)
costs related to restructuring activities, (ix) changes in
amortized cost of Partnership units liability, (x) change in fair
value of derivatives, (xi) consulting costs related to operational
transformation initiatives, (xii) corporate development related
costs and (xiii) loss (gain) on sale of shares. A reconciliation of
Adjusted EBITDA to the relevant reported results can be found in
the Segment and Geographic Results table of this news release.
COVID-19COVID-19 has resulted
in local governments enacting emergency measures to combat the
spread of the virus, with significant monetary and fiscal
interventions designed to stabilize economic conditions. Our
priorities during the COVID-19 pandemic continue to be to protect
the health and safety of our employees, while increasing the
availability of our products, which are essential to consumers each
and every day. It is difficult to estimate the length and potential
severity of the changed behaviours across our business segments or
reliably quantify the impact this pandemic could have on KPLP in
future periods.
Forward-Looking
StatementsCertain statements in this press release about
KPT’s and KPLP's current and future plans, expectations and
intentions, results, levels of activity, performance, goals or
achievements or any other future events or developments constitute
forward-looking statements. Forward-looking statements in this
press release include, but are not limited to, statements regarding
the projected capacity of the TAD Sherbrooke Project and the
Sherbrooke Expansion Project, expected revenue growth and KPLP’s
future business strategy. The words "may", "will", "would",
"should", "could", "expects", "plans", "intends", "trends",
"indications", "anticipates", "believes", "estimates", "predicts",
"likely" or "potential" or the negative or other variations of
these words or other comparable words or phrases, are intended to
identify forward-looking statements. The forward-looking statements
are based on certain key expectations and assumptions made by KPT
or KPLP. Although KPT and KPLP believe that the expectations and
assumptions on which such forward-looking information is based are
reasonable, undue reliance should not be placed on the
forward-looking statements since no assurance can be given that
such expectations and assumptions will prove to be correct.
The outlook provided in respect of Adjusted
EBITDA for Q2 2022 is forward-looking information and is subject to
the risk and uncertainties referred to below. The purpose of the
outlook is to provide the reader with an indication of management’s
expectations, at the date of this press release, regarding KPLP’s
future financial performance. Readers are cautioned that this
information may not be appropriate for other purposes.
Many factors could cause KPLP’s actual results,
level of activity, performance or achievements or future events or
developments (which could in turn affect the economic benefits
derived from KPT’s economic interest in KPLP), to differ materially
from those expressed or implied by the forward-looking statements,
including, without limitation, the following factors, which are
discussed in greater detail in the “Risk Factors – Risks Related to
KPLP’s Business” section of the KPT Annual Information Form dated
March 10, 2022 available on SEDAR at www.sedar.com: Kruger Inc.’s
influence over KPLP; KPLP’s reliance on Kruger Inc.; consequences
of an event of insolvency relating to Kruger Inc.; risks associated
with the TAD Sherbrooke Project; risks associated with the
Sherbrooke Expansion Project; operational risks; significant
increases in input costs; reduction in supply of fibre; increased
pricing pressure and intense competition; KPLP’s inability to
innovate effectively; adverse economic conditions; dependence on
key retail trade customers; damage to the reputation of KPLP or
KPLP’s brands; KPLP’s sales being less than anticipated; KPLP’s
failure to implement its business and operating strategies; KPLP’s
obligation to make regular capital expenditures; KPLP’s entering
into unsuccessful acquisitions; KPLP’s dependence on key personnel;
KPLP’s inability to retain its existing customers or obtain new
customers; KPLP’s loss of key suppliers; KPLP’s failure to
adequately protect its intellectual property rights; KPLP’s
reliance on third party intellectual property licenses; adverse
litigation and other claims affecting KPLP; material expenditures
due to comprehensive environmental regulation affecting KPLP’s cash
flow; KPLP’s pension obligations are significant and can be
materially higher than predicted if KPLP Management’s underlying
assumptions are incorrect; labour disputes adversely affecting
KPLP’s cost structure and KPLP’s ability to run its plants;
exchange rate and U.S. competitors; KPLP’s inability to service all
of its indebtedness; exposure to potential consumer product
liability; covenant compliance; interest rate and refinancing risk;
and risks relating to information technology; cyber-security;
insurance; internal controls; trade; and risks related to
COVID-19.
Readers should not place undue reliance on
forward-looking statements made herein. The forward-looking
information contained herein is expressly qualified in its entirety
by this cautionary statement. The forward-looking information
contained herein is made as of the date of press release and KPT
undertakes no obligation to publicly update such forward-looking
information to reflect new information, subsequent or otherwise,
unless required by applicable securities laws.
INFORMATION:
Francois ParoyanGeneral Counsel and Corporate
SecretaryKP Tissue Inc.Tel.:
905.812.6936francois.paroyan@krugerproducts.ca
INVESTORS:
Mike BaldesarraDirector of Investor RelationsKP
Tissue Inc. Tel.: 905.812.6962IR@KPTissueinc.com
Kruger
Products L.P. |
Unaudited
Condensed Consolidated Statement of Financial
Position |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
|
|
$ |
|
$ |
Assets |
|
|
|
Current assets |
|
|
|
|
Cash and cash equivalents |
110,026 |
|
|
148,519 |
|
|
Restricted
cash |
3,652 |
|
|
2,506 |
|
|
Trade and
other receivables |
97,447 |
|
|
88,802 |
|
|
Receivables
from related parties |
271 |
|
|
271 |
|
|
Advances to
partners |
- |
|
|
13,752 |
|
|
Inventories |
254,633 |
|
|
251,071 |
|
|
Income tax
recoverable |
425 |
|
|
1,171 |
|
|
Prepaid
expenses |
16,962 |
|
|
5,455 |
|
|
|
483,416 |
|
|
511,547 |
|
Non-current assets |
|
|
|
|
Property,
plant and equipment |
1,213,201 |
|
|
1,224,698 |
|
|
Right-of-use
assets |
90,899 |
|
|
91,626 |
|
|
Other
long-term assets |
34,624 |
|
|
37,456 |
|
|
Pensions |
47,188 |
|
|
- |
|
|
Goodwill |
152,021 |
|
|
152,021 |
|
|
Intangible
assets |
32,742 |
|
|
29,222 |
|
|
Deferred
income taxes |
84,493 |
|
|
75,742 |
|
Total assets |
2,138,584 |
|
|
2,122,312 |
|
|
|
|
|
|
Liabilities |
|
|
|
Current liabilities |
|
|
|
|
Trade and
other payables |
235,220 |
|
|
258,626 |
|
|
Payables to
related parties |
12,107 |
|
|
11,485 |
|
|
Income tax
payable |
68 |
|
|
300 |
|
|
Distributions payable |
12,397 |
|
|
12,300 |
|
|
Current
portion of provisions |
3,504 |
|
|
3,705 |
|
|
Current
portion of long-term debt |
33,459 |
|
|
48,550 |
|
|
Current
portion of lease liabilities |
29,809 |
|
|
30,170 |
|
|
|
326,564 |
|
|
365,136 |
|
Non-current liabilities |
|
|
|
|
Long-term
debt |
952,047 |
|
|
920,331 |
|
|
Long-term
lease liabilities |
81,018 |
|
|
82,354 |
|
|
Long-term
payable to related party |
43,038 |
|
|
42,454 |
|
|
Long-term
provisions |
6,799 |
|
|
6,929 |
|
|
Pensions |
- |
|
|
58,481 |
|
|
Post-retirement benefits |
49,764 |
|
|
57,331 |
|
|
Liabilities to non-unitholders |
1,459,230 |
|
|
1,533,016 |
|
|
Current
portion of Partnership units liability |
- |
|
|
14,064 |
|
|
Long-term
portion of Partnership units liability |
159,137 |
|
|
159,137 |
|
|
Total Partnership units liability |
159,137 |
|
|
173,201 |
|
Total liabilities |
1,618,367 |
|
|
1,706,217 |
|
|
|
|
|
|
Equity |
|
|
|
|
Partnership
units |
467,227 |
|
|
461,536 |
|
|
Deficit |
(14,655 |
) |
|
(117,123 |
) |
|
Accumulated
other comprehensive income |
67,645 |
|
|
71,682 |
|
Total equity |
520,217 |
|
|
416,095 |
|
Total equity and liabilities |
2,138,584 |
|
|
2,122,312 |
|
|
|
|
|
|
Kruger
Products L.P. |
Unaudited
Condensed Consolidated Statement of Comprehensive
Income |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month
period endedMarch 31, 2022 |
|
3-month
period ended March 31, 2021 |
|
$ |
|
$ |
|
|
|
|
Revenue |
398,739 |
|
|
310,379 |
|
|
|
|
|
Expenses |
|
|
|
Cost of sales |
363,855 |
|
|
263,331 |
|
Selling, general and administrative expenses |
28,855 |
|
|
27,765 |
|
Loss on sale of non-financial assets |
5 |
|
|
1 |
|
Restructuring costs, net |
516 |
|
|
56 |
|
|
|
|
|
Operating income |
5,508 |
|
|
19,226 |
|
|
|
|
|
Interest expense and other finance costs |
17,534 |
|
|
12,922 |
|
Other income |
(4,315 |
) |
|
(316 |
) |
|
|
|
|
Income (loss) before income taxes |
(7,711 |
) |
|
6,620 |
|
|
|
|
|
Income tax recovery |
(9,148 |
) |
|
(139 |
) |
|
|
|
|
Net
income for the period |
1,437 |
|
|
6,759 |
|
|
|
|
|
Other comprehensive income (loss) |
|
|
|
Items that will not be reclassified to net
income: |
|
|
|
Remeasurements of pensions |
105,621 |
|
|
97,447 |
|
Remeasurements of post-retirement benefits |
7,861 |
|
|
5,769 |
|
Items that may be subsequently reclassified to net
income: |
|
|
|
Cumulative translation adjustment |
(4,037 |
) |
|
(3,445 |
) |
|
|
|
|
Total other comprehensive income for the
period |
109,445 |
|
|
99,771 |
|
|
|
|
|
Comprehensive income for the period |
110,882 |
|
|
106,530 |
|
|
|
|
|
Kruger
Products L.P. |
Unaudited
Condensed Consolidated Statement of Cash Flows |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
|
|
3-month
period endedMarch 31, 2022 |
|
3-month
period endedMarch 31, 2021 |
|
$ |
|
$ |
Cash
flows from (used in) operating activities |
|
|
|
Net income for the period |
1,437 |
|
|
6,759 |
|
Items not
affecting cash |
|
|
|
Depreciation |
21,982 |
|
|
17,456 |
|
Amortization |
1,044 |
|
|
710 |
|
Change in amortized cost of Partnership units liability |
- |
|
|
3,428 |
|
Foreign exchange gain |
(4,315 |
) |
|
(3,744 |
) |
Interest expense and other finance costs |
17,534 |
|
|
12,922 |
|
Pension and post-retirement benefits |
3,694 |
|
|
4,002 |
|
Provisions |
(239 |
) |
|
652 |
|
Income tax recovery |
(9,148 |
) |
|
(139 |
) |
Loss on sale of non-financial assets |
5 |
|
|
1 |
|
Total items not affecting cash |
30,557 |
|
|
35,288 |
|
|
|
|
|
Net change
in non-cash working capital |
(46,490 |
) |
|
(122,455 |
) |
Contributions to pension and post-retirement benefit plans |
(4,183 |
) |
|
(3,809 |
) |
Provisions
paid |
(182 |
) |
|
(185 |
) |
Income tax
payments |
(320 |
) |
|
(91 |
) |
|
|
|
|
Net
cash used in operating activities |
(19,181 |
) |
|
(84,493 |
) |
|
|
|
|
Cash
flows from (used in) investing activities |
|
|
|
Purchases of
property, plant and equipment |
(499 |
) |
|
(2,845 |
) |
Purchases of
property, plant and equipment and software related to the TAD
Sherbrooke Project |
(5,331 |
) |
|
(50,479 |
) |
Purchases of
property, plant and equipment related to the Sherbrooke Expansion
Project |
(6,044 |
) |
|
- |
|
Interest
paid on credit facilities related to the TAD Sherbrooke
Project |
- |
|
|
(608 |
) |
Purchases of
software |
(4,455 |
) |
|
(738 |
) |
Proceeds on
sale of property, plant and equipment |
- |
|
|
2 |
|
|
|
|
|
Net
cash used in investing activities |
(16,329 |
) |
|
(54,668 |
) |
|
|
|
|
Cash
flows from (used in) financing activities |
|
|
|
Proceeds
from long-term debt |
141,956 |
|
|
104,640 |
|
Repayment of
long-term debt |
(118,539 |
) |
|
(1,642 |
) |
Payment of
deferred financing fees |
(2,135 |
) |
|
(324 |
) |
Payment of
lease liabilities |
(6,985 |
) |
|
(6,637 |
) |
Change in
Restricted cash |
(1,146 |
) |
|
- |
|
Interest
paid on long-term debt |
(8,893 |
) |
|
(7,006 |
) |
Distributions and advances paid, net |
(6,975 |
) |
|
(20,535 |
) |
|
|
|
|
Net
cash from (used in) financing activities |
(2,717 |
) |
|
68,496 |
|
|
|
|
|
Effect of exchange rate changes on cash and
cash |
|
|
|
equivalents held in foreign currency |
(266 |
) |
|
(522 |
) |
|
|
|
|
Decrease in cash and cash equivalents during the
period |
(38,493 |
) |
|
(71,187 |
) |
|
|
|
|
Cash
and cash equivalents - Beginning of period |
148,519 |
|
|
128,739 |
|
|
|
|
|
Cash
and cash equivalents - End of period |
110,026 |
|
|
57,552 |
|
|
|
|
|
Kruger
Products L.P. |
Segment and
Geographic Results |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
|
|
3-month
period ended March 31, 2022 |
|
3-month
period ended March 31, 2021 |
|
|
$ |
|
$ |
|
|
|
|
|
|
Segment Information |
|
|
|
|
|
|
|
|
|
Segment Revenue |
|
|
|
|
Consumer |
342,842 |
|
|
271,367 |
|
|
AFH |
55,897 |
|
|
39,012 |
|
|
|
|
|
|
|
Total
segment revenue |
398,739 |
|
|
310,379 |
|
|
|
|
|
|
|
Adjusted EBITDA |
|
|
|
|
Consumer |
35,383 |
|
|
44,051 |
|
|
AFH |
(3,221 |
) |
|
(4,782 |
) |
|
Corporate and other costs |
(3,107 |
) |
|
(1,804 |
) |
|
|
|
|
|
|
Total
Adjusted EBITDA |
29,055 |
|
|
37,465 |
|
|
|
|
|
|
|
Reconciliation to Net Income: |
|
|
|
|
|
|
|
|
|
Depreciation
and amortization |
23,026 |
|
|
18,166 |
|
|
Interest
expense and other finance costs |
17,534 |
|
|
12,922 |
|
|
Change in
amortized cost of Partnership units liability |
- |
|
|
3,428 |
|
|
Loss on sale
of non-financial assets |
5 |
|
|
1 |
|
|
Restructuring costs, net |
516 |
|
|
56 |
|
|
Foreign
exchange gain |
(4,315 |
) |
|
(3,744 |
) |
|
Corporate
development related costs |
- |
|
|
16 |
|
|
|
|
|
|
|
Income
(loss) before income taxes |
(7,711 |
) |
|
6,620 |
|
|
|
|
|
|
|
Income tax
recovery |
(9,148 |
) |
|
(139 |
) |
|
|
|
|
|
|
Net
income |
1,437 |
|
|
6,759 |
|
|
|
|
|
|
|
Geographic Revenue |
|
|
|
|
|
|
|
|
|
Canada |
242,920 |
|
|
194,603 |
|
|
US |
155,819 |
|
|
115,776 |
|
|
|
|
|
|
|
Total
revenue |
398,739 |
|
|
310,379 |
|
|
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statement of Financial Position |
(thousands
of Canadian dollars) |
|
|
|
|
|
|
|
|
|
March 31,
2022 |
|
December 31,
2021 |
|
$ |
|
$ |
Assets |
|
|
|
|
|
|
|
Current assets |
|
|
|
Distributions receivable |
1,788 |
|
|
1,781 |
|
Income tax recoverable |
277 |
|
|
208 |
|
|
2,065 |
|
|
1,989 |
|
|
|
|
|
Non-current assets |
|
|
|
Investment in associate |
89,923 |
|
|
78,727 |
|
|
|
|
|
Total Assets |
91,988 |
|
|
80,716 |
|
|
|
|
|
Liabilities |
|
|
|
|
|
|
|
Current liabilities |
|
|
|
Dividend payable |
1,788 |
|
|
1,781 |
|
Payable to Partnership |
246 |
|
|
246 |
|
Current portion of advances from Partnership |
- |
|
|
2,014 |
|
|
2,034 |
|
|
4,041 |
|
Non-current liabilities |
|
|
|
Deferred income taxes |
4,194 |
|
|
806 |
|
|
|
|
|
Total liabilities |
6,228 |
|
|
4,847 |
|
|
|
|
|
Equity |
|
|
|
|
|
|
|
Common shares |
22,226 |
|
|
21,844 |
|
Contributed surplus |
144,819 |
|
|
144,819 |
|
Deficit |
(93,457 |
) |
|
(103,561 |
) |
Accumulated other comprehensive income |
12,172 |
|
|
12,767 |
|
|
|
|
|
Total equity |
85,760 |
|
|
75,869 |
|
|
|
|
|
Total liabilities and equity |
91,988 |
|
|
80,716 |
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statement of Comprehensive Income |
(thousands
of Canadian dollars, except share and per share
amounts) |
|
|
|
|
|
3-month
period ended March 31, 2022 |
|
3-month
period ended March 31, 2021 |
|
$ |
|
$ |
|
|
|
|
Equity loss |
(1,108 |
) |
|
(345 |
) |
Dilution
gain |
73 |
|
|
80 |
|
|
|
|
|
Loss
before income taxes |
(1,035 |
) |
|
(265 |
) |
|
|
|
|
Income tax recovery |
(2,013 |
) |
|
(1,473 |
) |
|
|
|
|
Net
income for the period |
978 |
|
|
1,208 |
|
|
|
|
|
Other comprehensive income (loss) |
|
|
|
net of tax expense (recovery) |
|
|
|
Items that will not be reclassified to net
income: |
|
|
|
Remeasurements of pensions |
10,248 |
|
|
11,995 |
|
Remeasurements of post-retirement benefits |
670 |
|
|
516 |
|
Items that may be subsequently reclassified to net
income: |
|
|
|
Cumulative translation adjustment |
(595 |
) |
|
(545 |
) |
|
|
|
|
Total other comprehensive income for the
period |
10,323 |
|
|
11,966 |
|
|
|
|
|
Comprehensive income for the period |
11,301 |
|
|
13,174 |
|
|
|
|
|
Basic earnings per share |
0.10 |
|
|
0.12 |
|
|
|
|
|
Weighted average number of shares outstanding |
9,925,825 |
|
|
9,779,571 |
|
|
|
|
|
KP Tissue
Inc. |
Unaudited
Condensed Statement of Cash Flows |
(thousands
of Canadian dollars) |
|
|
|
|
|
3-month
period ended March 31, 2022 |
|
3-month
period ended March 31, 2021 |
|
$ |
|
$ |
Cash
flows from (used in) operating activities |
|
|
|
Net income for the period |
978 |
|
|
1,208 |
|
Items not
affecting cash |
|
|
|
Equity loss |
1,108 |
|
|
345 |
|
Dilution gain |
(73 |
) |
|
(80 |
) |
Income tax recovery |
(2,013 |
) |
|
(1,473 |
) |
Total items not affecting cash |
(978 |
) |
|
(1,208 |
) |
|
|
|
|
Net change
in non-cash working capital |
- |
|
|
(3 |
) |
Tax
payments |
(38 |
) |
|
(2,061 |
) |
Tax
Distribution received, net |
38 |
|
|
1,738 |
|
Advances
received |
- |
|
|
326 |
|
|
|
|
|
Net
cash from (used in) operating activities |
- |
|
|
- |
|
|
|
|
|
Cash
flows from investing activites |
|
|
|
Partnership
unit distributions received |
1,403 |
|
|
1,403 |
|
|
|
|
|
Net
cash from investing activities |
1,403 |
|
|
1,403 |
|
|
|
|
|
Cash
flows used in financing activities |
|
|
|
Dividends
paid, net |
(1,403 |
) |
|
(1,403 |
) |
|
|
|
|
Net
cash used in financing activities |
(1,403 |
) |
|
(1,403 |
) |
|
|
|
|
Increase (decrease) in cash and cash equivalents during the
period |
- |
|
|
- |
|
|
|
|
|
Cash
and cash equivalents - Beginning of period |
- |
|
|
- |
|
|
|
|
|
Cash
and cash equivalents - End of period |
- |
|
|
- |
|
|
|
|
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
KP Tissue (TSX:KPT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024